WO2022083586A1 - 半胱氨酸蛋白酶抑制剂sn与cathepsin l1复合物作为胃癌诊断标志物的应用 - Google Patents
半胱氨酸蛋白酶抑制剂sn与cathepsin l1复合物作为胃癌诊断标志物的应用 Download PDFInfo
- Publication number
- WO2022083586A1 WO2022083586A1 PCT/CN2021/124708 CN2021124708W WO2022083586A1 WO 2022083586 A1 WO2022083586 A1 WO 2022083586A1 CN 2021124708 W CN2021124708 W CN 2021124708W WO 2022083586 A1 WO2022083586 A1 WO 2022083586A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cathepsin
- antibody
- quantitative detection
- complex
- detection agent
- Prior art date
Links
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 28
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 27
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 27
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 title claims abstract description 11
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 title claims abstract description 11
- 229940094664 Cysteine protease inhibitor Drugs 0.000 title claims abstract description 11
- 239000003550 marker Substances 0.000 title abstract description 10
- 101000983585 Paramecium tetraurelia Cathepsin L 1 Proteins 0.000 title 1
- 102100026534 Procathepsin L Human genes 0.000 claims abstract description 39
- 108010028075 procathepsin L Proteins 0.000 claims abstract description 28
- 238000003745 diagnosis Methods 0.000 claims abstract description 23
- 238000004458 analytical method Methods 0.000 claims abstract description 13
- 238000001514 detection method Methods 0.000 claims description 50
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 19
- 108010026774 Salivary Cystatins Proteins 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 11
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 7
- 238000002965 ELISA Methods 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- 239000011534 wash buffer Substances 0.000 claims description 6
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 5
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
- 238000002649 immunization Methods 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 238000000749 co-immunoprecipitation Methods 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000004393 prognosis Methods 0.000 claims description 2
- 102000018968 Salivary Cystatins Human genes 0.000 claims 8
- 238000001179 sorption measurement Methods 0.000 claims 2
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 239000003547 immunosorbent Substances 0.000 claims 1
- 102100038387 Cystatin-SN Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 15
- 101000884768 Homo sapiens Cystatin-SN Proteins 0.000 description 11
- 101000983583 Homo sapiens Procathepsin L Proteins 0.000 description 11
- 238000011088 calibration curve Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108010059378 Endopeptidases Proteins 0.000 description 3
- 102000005593 Endopeptidases Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 108010084457 Cathepsins Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 102000015833 Cystatin Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011490 co-immunoprecipitation assay Methods 0.000 description 2
- 108050004038 cystatin Proteins 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229940123003 Cathepsin inhibitor Drugs 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 101100062319 Homo sapiens CST1 gene Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000000594 atomic force spectroscopy Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000011591 microinvasive gastric cancer Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96466—Cysteine endopeptidases (3.4.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (24)
- 半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物的定量检测剂在制备用于胃癌的诊断、辅助诊断或预后分析的试剂盒中的应用。
- 根据权利要求1所述的应用,其中,所述定量检测剂为所述半胱氨酸蛋白酶抑制剂SN以及所述Cathepsin L1的特异性抗体,所述抗体可用于执行免疫共沉淀或酶联免疫吸附试验以对所述半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物进行检测。
- 根据权利要求1所述的应用,其中,所述定量检测剂为所述半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物的特异性抗体。
- 根据权利要求3所述的应用,其中,所述特异性抗体为单克隆抗体或多克隆抗体。
- 根据权利要求4所述的应用,其中,所述特异性抗体由SEQ ID NO:1所示的氨基酸序列免疫得到。
- 根据权利要求3~5任一项所述的应用,其中,所述特异性抗体具有用于指示信号强度的标记。
- 根据权利要求6所述的应用,其中,所述用于指示信号强度的标记选自发色团、地高辛标记探针、电子致密物质、胶体金或酶中的任一种或多种。
- 一种用于胃癌的诊断、辅助诊断或预后分析的半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物的定量检测剂。
- 根据权利要求8所述的定量检测剂,其中,所述定量检测剂为所述半胱氨酸蛋白酶抑制剂SN以及所述Cathepsin L1的特异性抗体,所述抗体可用于执行免疫共沉淀或酶联免疫吸附试验以对所述半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物进行检测。
- 根据权利要求8所述的定量检测剂,其中,所述定量检测剂为所述半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物的特异性抗体。
- 根据权利要求10所述的定量检测剂,其中,所述特异性抗体为单克隆抗体或多克隆抗体。
- 根据权利要求11所述的定量检测剂,其中,所述特异性抗体由SEQ ID NO:1所示的氨基酸序列免疫得到。
- 根据权利要求10~12中任一项所述的定量检测剂,其中,所述特异性抗体具有用于指示信号强度的标记。
- 根据权利要求13所述的定量检测剂,其中,所述用于指示信号强度的标记选自发色团、地高辛标记探针、电子致密物质、胶体金或酶中的任一种或多种。
- 胃癌诊断、辅助诊断或预后分析试剂盒,,所述试剂盒包含权利要求3~7任一项中所定义的特异性抗体。
- 根据权利要求15所述的试剂盒,其特征在于,还包含固相载体、封闭液、显色剂、半胱氨酸蛋白酶抑制剂SN与Cathepsin L1融合抗原的校准品以及洗涤缓冲液中的至少一种。
- 根据权利要求16所述的试剂盒,其特征在于,所述固相载体为化学发光板。
- 一种胃癌的诊断、辅助诊断或预后分析的方法,所述方法包括:使用根据权利要求8所述的定量检测剂或根据权利要求15所述的试剂盒测量半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物的含量。
- 根据权利要求18所述的方法,其中,所述定量检测剂为所述半胱氨酸蛋 白酶抑制剂SN以及所述Cathepsin L1的特异性抗体,所述抗体可用于执行免疫共沉淀或酶联免疫吸附试验以对所述半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物进行检测。
- 根据权利要求19所述的方法,其中,所述定量检测剂为所述半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物的特异性抗体。
- 根据权利要求20所述的方法,其中,所述特异性抗体为单克隆抗体或多克隆抗体。
- 根据权利要求21所述的方法,其中,所述特异性抗体由SEQ ID NO:1所示的氨基酸序列免疫得到。
- 根据权利要求20~22中任一项所述的方法,其中,所述特异性抗体具有用于指示信号强度的标记。
- 根据权利要求23所述的方法,其中,所述用于指示信号强度的标记选自发色团、地高辛标记探针、电子致密物质、胶体金或酶中的任一种或多种。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011135409.6A CN112014578B (zh) | 2020-10-22 | 2020-10-22 | 半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物作为胃癌诊断标志物的应用 |
CN202011135409.6 | 2020-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022083586A1 true WO2022083586A1 (zh) | 2022-04-28 |
Family
ID=73527968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/124708 WO2022083586A1 (zh) | 2020-10-22 | 2021-10-19 | 半胱氨酸蛋白酶抑制剂sn与cathepsin l1复合物作为胃癌诊断标志物的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112014578B (zh) |
WO (1) | WO2022083586A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112379093B (zh) * | 2020-10-22 | 2023-06-16 | 上海良润生物医药科技有限公司 | CST-Cathepsin复合物作为肿瘤诊断标志物的应用 |
CN112014578B (zh) * | 2020-10-22 | 2021-01-22 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物作为胃癌诊断标志物的应用 |
CN113957147A (zh) * | 2021-10-27 | 2022-01-21 | 江南大学附属医院 | 一种双基因组合及其在胃癌免疫治疗患者个性化候选评估中的应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090123925A1 (en) * | 2005-09-23 | 2009-05-14 | Collie-Duguid Elaina S R | Cancer therapy prognosis and target |
CN103898205A (zh) * | 2013-05-07 | 2014-07-02 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂sn的应用 |
CN103901205A (zh) * | 2013-05-07 | 2014-07-02 | 上海良润生物医药科技有限公司 | Cystatin SN与CYFRA21-1在制备诊断和预示食管癌标志物中的应用 |
US20160138113A1 (en) * | 2013-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the diagnosis, prognosis and treatment of brain metastasis |
CN107688095A (zh) * | 2017-08-19 | 2018-02-13 | 杭州飞悦生物技术有限公司 | 检测人胱抑素sn的酶联免疫试剂盒及制备方法及检测方法 |
CN107870245A (zh) * | 2017-11-30 | 2018-04-03 | 深圳市老年医学研究所 | 基于唾液蛋白质组学的慢性肾炎生物标志物检测的方法 |
CN108152508A (zh) * | 2017-11-30 | 2018-06-12 | 深圳市老年医学研究所 | 一种无创伤胃癌唾液生物标记物的筛选方法 |
CN112014578A (zh) * | 2020-10-22 | 2020-12-01 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物作为胃癌诊断标志物的应用 |
CN112379093A (zh) * | 2020-10-22 | 2021-02-19 | 上海良润生物医药科技有限公司 | CST-Cathepsin复合物作为肿瘤诊断标志物的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2762082C (en) * | 2009-05-15 | 2018-06-19 | Pacific Edge Biotechnology Limited | Markers for detection of gastric cancer |
WO2013158722A1 (en) * | 2012-04-17 | 2013-10-24 | The Cleveland Clinic Foundation | Diagnosis of lymph node involvement in rectal cancer |
-
2020
- 2020-10-22 CN CN202011135409.6A patent/CN112014578B/zh active Active
-
2021
- 2021-10-19 WO PCT/CN2021/124708 patent/WO2022083586A1/zh active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090123925A1 (en) * | 2005-09-23 | 2009-05-14 | Collie-Duguid Elaina S R | Cancer therapy prognosis and target |
CN103898205A (zh) * | 2013-05-07 | 2014-07-02 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂sn的应用 |
CN103901205A (zh) * | 2013-05-07 | 2014-07-02 | 上海良润生物医药科技有限公司 | Cystatin SN与CYFRA21-1在制备诊断和预示食管癌标志物中的应用 |
US20160138113A1 (en) * | 2013-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the diagnosis, prognosis and treatment of brain metastasis |
CN107688095A (zh) * | 2017-08-19 | 2018-02-13 | 杭州飞悦生物技术有限公司 | 检测人胱抑素sn的酶联免疫试剂盒及制备方法及检测方法 |
CN107870245A (zh) * | 2017-11-30 | 2018-04-03 | 深圳市老年医学研究所 | 基于唾液蛋白质组学的慢性肾炎生物标志物检测的方法 |
CN108152508A (zh) * | 2017-11-30 | 2018-06-12 | 深圳市老年医学研究所 | 一种无创伤胃癌唾液生物标记物的筛选方法 |
CN112014578A (zh) * | 2020-10-22 | 2020-12-01 | 上海良润生物医药科技有限公司 | 半胱氨酸蛋白酶抑制剂SN与Cathepsin L1复合物作为胃癌诊断标志物的应用 |
CN112379093A (zh) * | 2020-10-22 | 2021-02-19 | 上海良润生物医药科技有限公司 | CST-Cathepsin复合物作为肿瘤诊断标志物的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112014578A (zh) | 2020-12-01 |
CN112014578B (zh) | 2021-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022083586A1 (zh) | 半胱氨酸蛋白酶抑制剂sn与cathepsin l1复合物作为胃癌诊断标志物的应用 | |
WO2022083603A1 (zh) | 半胱氨酸蛋白酶抑制剂与Cathepsin复合物作为肿瘤诊断标志物的应用 | |
EP1137943B1 (en) | Cancer detection method and reagents | |
WO2022083582A1 (zh) | 半胱氨酸蛋白酶抑制剂SN与Cathepsin B复合物作为结肠直肠癌诊断标志物的应用 | |
US8288110B2 (en) | Biomarkers for detecting cancer | |
JP2009527735A (ja) | 癌に対するバイオマーカーとしての遊離ngal | |
WO2022063156A1 (zh) | 乳腺癌的生物标志物及其应用 | |
WO2022083580A1 (zh) | 半胱氨酸蛋白酶抑制剂SN与Cathepsin H复合物作为食管癌诊断标志物的应用 | |
WO2010032458A1 (ja) | 新規非アルコール性脂肪性肝疾患バイオマーカーおよび該バイオマーカーを用いた非アルコール性脂肪性肝疾患の検出方法 | |
WO2012173228A1 (ja) | 3´硫酸化コア1糖鎖に結合するプローブを用いるムチン1の分析方法、及び乳癌の検出又はモニタリング方法 | |
US20220236275A1 (en) | Cancer test method | |
WO2006119262A2 (en) | Detection of carbohydrate biomarkers | |
Tejerina-Miranda et al. | Angiogenesis inhibitor or aggressiveness marker? The function of endostatin in cancer through electrochemical biosensing | |
JPWO2011138955A1 (ja) | Siaα2−8Siaα2−3Galβ−R糖鎖を持つムチン1の分析方法 | |
JP5653725B2 (ja) | 筋萎縮性側索硬化症マーカー及びその利用 | |
WO2021246153A1 (ja) | 膵臓がんの検出方法及び検出試薬 | |
KR20190139289A (ko) | 분석 및 치료 방법과 조성물, 그리고 이의 용도 | |
WO2005094422A2 (en) | Angiocidin fragments and uses thereof in clinical assays for cancer and other diseases | |
CA2702623A1 (en) | Use of tenascin-w as a biomarker for colon cancer | |
WO2021261483A1 (ja) | 腺癌の検出方法及び検査キット | |
WO2021172000A1 (ja) | 卵巣悪性腫瘍の検出方法及び検出試薬 | |
KR101652894B1 (ko) | 대장암에 대한 신규 바이오마커 및 그의 용도 | |
JP2003527607A (ja) | 乳癌の検出および診断のための新規バイオマーカーとしてのリソソームペプスタチン非感受性タンパク質分解酵素 | |
CA2852757A1 (en) | Predictive biomarkers for breast cancer | |
US20030211554A1 (en) | Lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21882002 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21882002 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21882002 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16/10/2023) |